Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | $561.90M |
| Gross Profit (TTM) | $414.44M |
| EBITDA | $113.52M |
| Operating Margin | 15.30% |
| Return on Equity | 8.77% |
| Return on Assets | 4.09% |
| Revenue/Share (TTM) | $7.08 |
| Book Value | $16.50 |
| Price-to-Book | 2.39 |
| Price-to-Sales (TTM) | 6.02 |
| EV/Revenue | 5.11 |
| EV/EBITDA | 20.98 |
| Quarterly Earnings Growth (YoY) | 288.90% |
| Quarterly Revenue Growth (YoY) | 15.50% |
| Shares Outstanding | $80.39M |
| Float | $79.88M |
| % Insiders | 0.54% |
| % Institutions | 113.53% |
Volatility is currently contracting
Veracyte (VCYT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Veracyte's core tests are Decipher and Afirma. Both of these tests are producing double-digit growth with improving margins. I think that bodes well for VCYT's potential as a long-term cash flow machine. Moreover, VCYT's Prosigna and TrueMRD add more long-term upside, which management hasn't yet included in its recent 2026 testing-revenue guidance.
Veracyte (VCYT) is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence, specialist relationships, and reimbursement infrastructure. Q2 2026 results showed 15% revenue growth, 23% adjusted EBITDA growth, and 29.2% EBITDA margin, with robust cash generation and no funded debt. Prosigna and TrueMRD launches offer significant upside, as 2026 guidance excludes their contributions, while Decipher and Afirma drive core growth and margin expansion.
Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript
Grew total revenue to $150.3 million and testing revenue to $145.7 million , representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.
SOUTH SAN FRANCISCO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following investor conferences:
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market on Thursday, July 30, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will b.
Veracyte (VCYT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
VCYT's 117% stock surge is driven by durable growth plans, Afirma demand, TrueMRD progress, international IVD efforts and a debt-free balance sheet.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VCYT and any ticker you trade — then tracks every position and per-strategy win rate.
